Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Crossover Study to Demonstrate Bioequivalence Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects

Trial Profile

A Randomized, Open-Label, Crossover Study to Demonstrate Bioequivalence Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs Perampanel (Primary)
  • Indications Epilepsy; Partial epilepsies; Seizures; Tonic-clonic epilepsy
  • Focus Pharmacokinetics
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 26 Oct 2018 Status changed from active, no longer recruiting to completed.
    • 22 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top